Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

References

• Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31–40.
   PubMed Web of Science ®Google Scholar
• Kim BY, Won JC, Lee JH, et al. Diabetes fact sheets in Korea, 2018: an appraisal of current status. Diabetes Metab J. 2019;43(4):487–494.
   PubMedGoogle Scholar
• Schott G, Martinez YV, Ediriweera de Silva RE, et al. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. BMC Geriatr. 2017;17(Suppl 1):226.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kang ES, Jang HC, et al. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2019;21(3):631–639.
   PubMed Web of Science ®Google Scholar
• Lukashevich V, Del Prato S, Araga M, Kothny W. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16(5):403–409.
   PubMedGoogle Scholar
• Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013;6:187–195.
   PubMedGoogle Scholar
• Hong S, Park CY, Han KA, et al. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled Phase III trial. Diabetes Obes Metab. 2016;18(5):528–532.
   PubMed Web of Science ®Google Scholar
• Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Expert Opin Pharmacother. 2016;17(10):1309–1316.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab. 2014;16(5):418–425.
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Kondo K, Sasaki N, et al. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother. 2017;18(13):1291–1300.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251–260.
   PubMed Web of Science ®Google Scholar
• Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997;10(7 Pt 1):697–704.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 12. Older adults: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S152–S162.
   PubMedGoogle Scholar
• Han E, Park HS, Kwon O, et al. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine (Baltimore). 2016;95(44):e5155.
   PubMed Web of Science ®Google Scholar
• Kim MK, Ko SH, Kim BY, et al. 2019 clinical practice guidelines for Type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98–S110.
   PubMedGoogle Scholar
• Wang J, Geiss LS, Williams DE, Gregg EW. Trends in emergency department visit rates for hypoglycemia and hyperglycemic crisis among adults with diabetes, United States, 2006-2011. PLoS One. 2015;10(8):e0134917.
   PubMed Web of Science ®Google Scholar
• Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434(2):191–196.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012;20(19):5705–5719.
   PubMed Web of Science ®Google Scholar
• Kurozumi A, Okada Y, Sugai K, Torimoto K, Tanaka Y. Comparison of the effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with different half-lives, on glucose fluctuation and glucagon-like peptide-1 in Type 2 diabetes mellitus. J UOEH. 2018;40(1):1–9.
   PubMedGoogle Scholar
• Zhang Z, Jin X, Yang C, Li Y. Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury. Biomed Pharmacother. 2019;109:468–474.
   PubMed Web of Science ®Google Scholar
• Lei Zhang WY, Kongab X, Zhang B. Teneligliptin protects against ischemia/reperfusion-induced endothelial permeability in vivo and in vitro. RSC Adv. 2020;10:3765.
   PubMedGoogle Scholar
• Esposito K, Chiodini P, Capuano A, Maiorino MI, Bellastella G, Giugliano D. Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine. 2014;46(1):43–51.
   PubMedGoogle Scholar
• Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892.
   PubMed Web of Science ®Google Scholar
• Choe EY, Cho Y, Choi Y, et al. The effect of DPP-4 inhibitors on metabolic parameters in patients with Type 2 diabetes. Diabetes Metab J. 2014;38(3):211–219.
   PubMedGoogle Scholar
• Strain WD, McEwan P, Howitt H, Meadowcroft S. Retrospective database analysis evaluating the clinical outcomes of changing treatment of people with Type 2 Diabetes Mellitus (T2DM) from other DPP-4 inhibitor therapy to alogliptin in a primary care setting. Diabetes Ther. 2019;10(4):1499–1507.
   PubMedGoogle Scholar
• Kim HJ, Kim YS, Lee CB, et al. Efficacy and safety of switching to teneligliptin in patients with Type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: a 12-week interim report. Diabetes Ther. 2019;10(4):1271–1282.
   PubMed Web of Science ®Google Scholar
• Son JW, Kim S. Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with Type 2 diabetes: a tale of three studies. Diabetes Metab J. 2015;39(5):373–383.
   PubMedGoogle Scholar
• Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018.
   Google Scholar
• Kim MJ, Kim NY, Jung YA, et al. Evogliptin, a Dipeptidyl Peptidase-4 inhibitor, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice. Diabetes Metab J. 2020;44(1):186–192.
   PubMedGoogle Scholar
• Gangadharan Komala M, Gross S, Zaky A, Pollock C, Panchapakesan U. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology (Carlton). 2016;21(5):423–431.
   PubMed Web of Science ®Google Scholar
• Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63(6):2120–2131.
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–3468.
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab. 2017;19(11):1610–1619.
   PubMed Web of Science ®Google Scholar
• Nakamaru Y, Akahoshi F, Iijima H, Hisanaga N, Kume T. Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase-4 inhibitors. Biopharm Drug Dispos. 2016;37(3):142–155.
   PubMed Web of Science ®Google Scholar
• Kitada M, Ogura Y, Nitta K, et al. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease. J Diabetes Investig. 2019;10(3):706–713.
   PubMed Web of Science ®Google Scholar
• Dennis JM, Shields BM, Hill AV, et al. Precision medicine in Type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy. Diabetes Care. 2018;41(4):705–712.
   PubMed Web of Science ®Google Scholar
• Shimoda M, Miyoshi-Takai M, Irie S, et al. Inadequate triglyceride management worsens the durability of dipeptidyl peptidase-4 inhibitor in subjects with Type 2 diabetes mellitus. J Diabetes Res. 2017;2017:5856475.
   PubMedGoogle Scholar
• Hodson DJ, Mitchell RK, Bellomo EA, et al. Lipotoxicity disrupts incretin-regulated human beta cell connectivity. J Clin Invest. 2013;123(10):4182–4194.
   PubMedGoogle Scholar
• Cigliola V, Chellakudam V, Arabieter W, Meda P. Connexins and beta-cell functions. Diabetes Res Clin Pract. 2013;99(3):250–259.
   PubMedGoogle Scholar